ArticleAnnals of medicine2023
Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients.
Article in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Asymptomatic COVID-19 among university students during the low-risk transmission period.BMC infectious diseases · 2026Article
- From Immunization to Autoimmunity: A Deep Dive Into Post-COVID-19 Vaccine Reactions-A Narrative Review.Health science reports · 2026Article
- The impact of COVID-19 vaccine distribution channels on equity-deserving populations: a Canadian population-based cohort study using administrative data.BMC public health · 2026Article
- Comparison of two nanomaterial labels for detection of SARS-CoV-2 nucleocapsid antigen to improve analytical performance of lateral flow immunoassays.RSC advances · 2025Article
- Long COVID and the kidney.Nature reviews. Nephrology · 2025Review
- Dynamic effects of COVID-19 vaccination on major acute cardiovascular events and mortality following SARS-CoV-2 infection in a target trial emulation study.Scientific reports · 2025Article
- Article
- Relationship Between Acute SARS-CoV-2 Viral Clearance and Long COVID-19 (Long COVID) Symptoms: A Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Impact of QazVac vaccination on clinical manifestations and immune responses in post-COVID syndrome: a cross-sectional study.Frontiers in medicine · 2025Article
- Factors Influencing COVID-19 Viral Clearance: Implications for Vaccination and Antiviral Therapy.Infection and drug resistance · 2025Article
- Scrutinizing the COVID-19 vaccine safety debate.Human vaccines & immunotherapeutics · 2024Article
- Article
- Infectious Disease as a Modifiable Risk Factor for Dementia: A Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- Epidemiological and clinical characteristics of long COVID-19 among Iranians: A community-based study in southern Iran.BMC public health · 2024Article
- Relationship between acute SARS-CoV-2 viral clearance with Long COVID Symptoms: a cohort study.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to investigate vaccine effectiveness in relieving symptoms in patients with the SARS-CoV-2 delta (B.1.617.2) variant.
methodsIn this retrospective study, 31 patients did not receive any vaccine (non-vaccination, NV), 21 patients received 1-dose of inactivated vaccine (one-dose vaccination, OV), and 60 patients received at least 2-dose inactivated vaccine (two-dose vaccination, TV). The baseline data, clinical outcomes and vaccination information were collected and analyzed.
resultsPatients in the OV group were younger than those in the other two groups (
conclusionsOur results suggest that 2-dose vaccination can reduce viral load and accelerate viral clearance in patients with the delta variant and enhance the protection afforded by IgG antibodies
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.